Neoantigen Sequencing Service

Neoantigen sequencing is a specialized approach designed to identify tumor-specific antigens generated by somatic mutations. These neoantigens arise from changes in protein sequences caused by genetic alterations in tumor cells. Since they are typically only expressed in tumor cells, the immune system recognizes them as “non-self” antigens, capable of triggering a targeted immune response. Neoantigen sequencing involves genome and transcriptome sequencing of tumor samples, computational analysis, and validation through proteomics and immunological methods to systematically identify and assess the presence and immunogenicity of these neoantigens.

 

Neoantigen sequencing service has broad applications in cancer immunotherapy and vaccine development. For example, identifying neoantigens can aid in creating tumor-specific vaccines, T-cell receptor (TCR) therapies, or chimeric antigen receptor (CAR)-T cell therapies to boost the immune system’s ability to target tumors. In addition, neoantigen sequencing is utilized to investigate the complexity of the tumor immune microenvironment, uncover mechanisms of immune evasion, and identify potential biomarkers. This provides essential insights and data for advancing precision medicine and immunotherapy.

 



Biernacki, M A. et al. Frontiers in Immunology, 2020.

Figure 1. Schematic Representation of Different Classes of Non-Viral Neoantigens.

 

Services at MtoZ Biolabs

Based on the high-resolution mass spectrometry (LC-MS/MS) platform, combined with genome sequencing and bioinformatics analysis processes, MtoZ Biolabs' neoantigen sequencing service can comprehensively analyze the amino acid sequence information of mutated neoantigens in tumor samples. By extracting proteins from patient tumor samples, enzymatically digesting them into peptides, and employing high-efficiency mass spectrometry detection combined with computational analysis, MtoZ Biolabs accurately identifies tumor-specific antigens resulting from genetic mutations. The service ensures highly sensitive and high-resolution modified peptide data, along with clear mutation-derived antigen profiles, offering comprehensive candidate neoantigen information to support cancer immunotherapy.

 

Service Advantages

1. Accurate Antigen Identification

MtoZ Biolabs uses high-throughput sequencing technologies to precisely identify mutated antigens on the surface of tumor cells or pathogens, providing reliable targets for immunotherapy.

 

2. High Sensitivity

Using advanced mass spectrometry platforms, we efficiently screen for neoantigens from complex biological samples, ensuring comprehensive coverage with no missed targets.

 

3. Large-scale Data Analysis

With robust data processing capabilities, we perform in-depth analysis on large-scale genomic datasets, delivering comprehensive antigen profiles.

 

4. Customized Services

MtoZ Biolabs offers tailor-made antigen screening and identification solutions based on clients’ research needs, ensuring results with high relevance and practical utility.

 

Applications

1. Cancer Immunotherapy

Neoantigen sequencing service identifies tumor-specific mutations, helping to pinpoint patient-specific cancer neoantigens. This provides potential targets for personalized cancer immunotherapy, advancing individualized treatment approaches.

 

2. Cancer Vaccine Development

Accurate neoantigen identification supports the development of personalized cancer vaccines. This enhances vaccine specificity and efficacy, boosting immune responses against tumors.

 

3. Tumor Immunomonitoring

By detecting neoantigens, it is possible to evaluate a patient’s immune response and tumor microenvironment changes, providing valuable guidance for monitoring immune efficacy and optimizing treatment strategies.

 

4. Clinical Treatment Optimization

Neoantigen sequencing service can help identify the most suitable immune checkpoint inhibitors or other immunotherapeutic agents for cancer patients, ultimately enhancing therapeutic outcomes.

 

Case Study

1. Utilization of primary tumor samples for cancer neoantigen discovery

This paper evaluates the feasibility and advantages of using primary tumor samples for neoantigen sequencing, with a focus on their critical role in the neoantigen discovery process. The study encompasses various types of primary solid tumors, employing high-throughput DNA and RNA sequencing combined with mass spectrometry to identify tumor mutations and translation products. Advanced bioinformatics algorithms are used to predict neoantigen sequences. The results demonstrate that primary tumor samples provide high-quality mutation data and transcriptomic information, significantly improving the accuracy of neoantigen sequencing and enabling precise identification of potential neoantigen candidates and their binding affinity to MHC molecules. The paper concludes that neoantigen sequencing based on primary tumor samples offers a comprehensive view of patient-specific tumor antigen repertoires, presenting a wealth of potential targets and promising clinical applications in cancer immunotherapy.

 



Leko, V. et al.Journal for ImmunoTherapy of Cancer, 2025.

Figure 2. The Design and Analysis of the Study.

 

Deliverables

1. Comprehensive Experimental Details

 

2. Materials, Instruments, and Methods

 

3. Data Analysis, Preprocessing, and Estimation 

 

4. Bioinformatics Analysis

 

5. Raw Data

 

FAQ

Q1: What is the difference between neoantigen sequencing and antigen sequencing?

A1: Neoantigen sequencing focuses on identifying unique neoantigens caused by mutations in cancer cells, which could serve as targets for cancer immunotherapy. Traditional antigen sequencing, on the other hand, emphasizes studying known antigens that play a role in the immune system, often for vaccine development or immune response research. The main difference is that neoantigen sequencing centers on cancer-related mutant antigens, while antigen sequencing is more broadly concerned with various known immune-related antigens.

 

MtoZ Biolabs, an integrated Chromatography and Mass Spectrometry (MS) Services Provider, provides advanced proteomics, metabolomics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. Our ultimate aim is to provide more rapid, high-throughput, and cost-effective analysis, with exceptional data quality and minimal sample consumption. Free project evaluation, welcome to learn more details!